Serelaxin treatment does not reduce incidence of death in patients with AHF
Sign Up to like & getrecommendations! Published in 2019 at "Nature Reviews Cardiology"
DOI: 10.1038/s41569-019-0264-4
Abstract: In patients with acute heart failure, treatment with serelaxin, a recombinant form of human relaxin 2, did not reduce the incidence of cardiovascular death or worsening heart failure. read more here.
Keywords: serelaxin treatment; death; treatment; reduce incidence ... See more keywords